13 Oct 2015
Co-development partner initiates Phase II
The commencement of Dilaforette’s Phase II trial with sevaparin in patients with sickle-cell disease is encouraging and marks the first milestone in Ergomed’s Orphan drug co-development deal. Data is expected in H2 2016. The five current co-development deals offer potentially very attractive returns with clinical data from 4 due between now and the end of 2016, providing upside potential to our 290p TP. We remain at Buy and look forward to data from the group’s co-development deals.